Common variable immunodeficiency

Jump to navigation Jump to search
Common variable immunodeficiency
ICD-10 D83
ICD-9 279.06
OMIM 240500
DiseasesDB 3274
MeSH D017074

WikiDoc Resources for Common variable immunodeficiency

Articles

Most recent articles on Common variable immunodeficiency

Most cited articles on Common variable immunodeficiency

Review articles on Common variable immunodeficiency

Articles on Common variable immunodeficiency in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Common variable immunodeficiency

Images of Common variable immunodeficiency

Photos of Common variable immunodeficiency

Podcasts & MP3s on Common variable immunodeficiency

Videos on Common variable immunodeficiency

Evidence Based Medicine

Cochrane Collaboration on Common variable immunodeficiency

Bandolier on Common variable immunodeficiency

TRIP on Common variable immunodeficiency

Clinical Trials

Ongoing Trials on Common variable immunodeficiency at Clinical Trials.gov

Trial results on Common variable immunodeficiency

Clinical Trials on Common variable immunodeficiency at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Common variable immunodeficiency

NICE Guidance on Common variable immunodeficiency

NHS PRODIGY Guidance

FDA on Common variable immunodeficiency

CDC on Common variable immunodeficiency

Books

Books on Common variable immunodeficiency

News

Common variable immunodeficiency in the news

Be alerted to news on Common variable immunodeficiency

News trends on Common variable immunodeficiency

Commentary

Blogs on Common variable immunodeficiency

Definitions

Definitions of Common variable immunodeficiency

Patient Resources / Community

Patient resources on Common variable immunodeficiency

Discussion groups on Common variable immunodeficiency

Patient Handouts on Common variable immunodeficiency

Directions to Hospitals Treating Common variable immunodeficiency

Risk calculators and risk factors for Common variable immunodeficiency

Healthcare Provider Resources

Symptoms of Common variable immunodeficiency

Causes & Risk Factors for Common variable immunodeficiency

Diagnostic studies for Common variable immunodeficiency

Treatment of Common variable immunodeficiency

Continuing Medical Education (CME)

CME Programs on Common variable immunodeficiency

International

Common variable immunodeficiency en Espanol

Common variable immunodeficiency en Francais

Business

Common variable immunodeficiency in the Marketplace

Patents on Common variable immunodeficiency

Experimental / Informatics

List of terms related to Common variable immunodeficiency

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Synonyms and keywords: CVID; common variable hypogammaglobulinaemia; non-familial hypogammaglobulinaemia; acquired hypogammaglobulinemia; immunodeficiency, common variable; late-onset immunoglobulin deficiency

Overview

Common variable immunodeficiency (CVID) is a group of 20-30 primary immunodeficiencies (PIDs) which have a common set of symptoms but with different underlying causes.

Historyical Perspective

Charles Janeway et al (1953) is generally credited with the description of the first case of CVID.[1]

Classification

Types of CVID include:

Type Gene
CVID1 ICOS
CVID2 TACI
CVID3 CD19
CVID4 TNFRSF13C
CVID5 CD20
CVID6 CD81

Pathophysiology

CVID is believed to be a genetically determined primary immune defect; however, the underlying causes are different. The result of these defects is that the patient doesn't produce sufficient antibodies in response to exposure to pathogens. As a result, the patient's immune system fails to protect them against common bacterial and viral (and occasionally parasitic and protozoan) infections. The net result is that the patient is susceptible to illness. Both parts of the immune system (the cellular and humoral system) are affected, hence its classification as a combined immunodeficiency.

CVID appears to include a number of defects, some of which have been identified. For the majority, the genetic causes are still unknown. It is possible that environmental agents provoke the immune defect, due to genetic predisposition, but this has not been clarified.

See also X-linked agammaglobulinemia, a similar disorder, better characterised than CVID. Hypogammaglobulinemia (CVID) and X-linked agammaglobulinemia (XLA) are often intermixed by physicians, as their clinical conditions and treatment are almost identical.

Differentiating from other Diseases

CVID should be differentiated from the following diseases:

Epidemiology

Prevalence

CVID has an estimated prevalence ranging from a low of 2 per 100,000 to a high of 4 per 100,000 with an average of 3 per 100,000.

Age

The typical patient is between 20 and 40. About 20% of patients are diagnosed in childhood.

Gender

Males and females are equally affected

Diagnosis

Symptoms

Symptoms of CVID are:

Physical Examination

Head

  • Swelling of the lymph glands

Abdomen

Laboratory Findings

  • Complete blood count and differential count - Lymphocytopenia
  • Blood culture
  • Hypogammaglobulinemia, or low levels of immunoglobulin G (IgG), IgA and/or IgM. Lack of normal levels of antibody in the serum is part of the diagnosis
  • Poor titer levels in response to vaccination. Responsiveness may be tested after administration of polysaccharide and non-polysaccharide coated pathogens (e.g. streptococci and tetanus respectively)

Diagnosis is often delayed; and diagnosis is often made in the second or third decade of life after referral to an immunologist.

As with several other immune cell disorders, CVID may predispose to lymphoma or possibly stomach cancer. There also appears to be a predilection for autoimmune diseases, with a risk of up to 25%. Autoimmune destruction of platelets or red cells are the commonest of these.

Treatment

Treatment usually consists of immunoglobulin therapy, which is an injection of human antibodies harvested from blood donations:

  • Intravenous immunoglobulin (IVIG, most common treatment)
  • Subcutaneous immunoglobulin G (SCIG, relatively new therapy)
  • Intramuscular immunglobulin (IMIG, less effective, painful).

This is not a cure, but it strengthens immunity by ensuring that the patient has "normal" levels of antibodies, which helps to prevent recurrent upper respiratory infections.

IG therapy can't be used if the patient has anti-IgA antibodies but in this case, products low in IgA can be used; subcutaneous delivery also is a means of permitting such patients to have adequate antibody replacement.

IVIG treatment can be received by patients with a complete IgA deficiency if the IgA is completely removed from the treatment.

Some CVID patients may experience reactions to IG therapies; reactions may include:

  • Anaphylactic shock (very rare)
  • Hives (rare)
  • difficulty breathing
  • Headache (relatively common, may be relieved by an antihistamine, paracetamol/acetaminophen, or an anti-inflammatory (naproxen, advil, aspirin)
  • Nausea (common)
  • Fever (common)
  • Aseptic meningitis (rare)
  • Severe fatigue
  • Muscle aches and pain, or joint pain
  • Thrombotic events (rare)

Patients should not receive therapy if they are fighting an active infection as this increases the risk of reaction. Also, patients changing from one brand of product to another may be at higher risk of reaction for the first couple of treatments on the new brand.

Reactions can be minimised by taking an antihistamine and/or hydrocortisone and some paracetamol/acetaminophen/anti-inflammatory (naproxen, advil, aspirin) prior to treatment; patients should also be thoroughly hydrated and continue to drink water before, after and during treatment (if possible).

Research

Research is currently focussing on genetic analysis, and in differentiating between the various different disorders in order to allow a cure to be developed. Cures are likely to be genetic in nature, repairing faulty genes and allowing the individual to start producing antibodies. Funding for research in the US is provided by the National Institutes of Health. Key research in the UK is funded by the Primary Immunodeficiency Association (PiA), and funding is raised through the annual Jeans for Genes campaign.

References

  1. Janeway CA, Apt L, Gitlin D. Agammaglobulinemia. Trans Assoc Am Physicians 1953;66:200-2. PMID 13136263

External links


Template:WikiDoc Sources